미국의 전임상 CRO 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 개발 단계별, 적응증별, 모델 유형별, 최종 용도별 및 부문 예측(2026-2033년)

U.S. Preclinical CRO Market Summary

The U.S. preclinical CRO market size was valued at USD 1.7 billion in 2025 and is projected to grow from USD 1.8 billion in 2026 to USD 3.1 billion by 2033, at a CAGR of 7.7% from 2026 to 2033. The market is experiencing steady growth, driven by factors including the complexities of drug discovery, increased demand for advanced therapies, and greater outsourcing by pharmaceutical and biotechnology firms. Preclinical CROs are crucial to supporting early-stage drug development, offering services such as pharmacology, toxicology, bioanalysis, DMPK studies, safety assessment, efficacy testing, disease modeling, and IND-enabling studies.

Moreover, the U.S. preclinical CRO industry benefits from a robust biopharmaceutical sector, significant R&D investments, advanced laboratory infrastructure, and a well-defined regulatory environment. Besides, one of the key drivers of market growth is the increased focus on personalized medicine and targeted therapies. These approaches target specific patient populations, disease subtypes, or genetic profiles, necessitating thorough preclinical evaluations. Sponsors are increasingly seeking sophisticated in vitro and in vivo models to evaluate mechanisms of action, efficacy, safety, pharmacokinetics, and toxicity prior to clinical trials. This trend is fueling the requirement for specialized CRO expertise, particularly in oncology, rare diseases, neurological disorders, autoimmune diseases, and genetic disorders.

In addition, the expanding pipeline of biologics, cell and gene therapies, radiopharmaceuticals, and other innovative modalities is further supporting the U.S. preclinical CRO market. These advanced therapies typically require more intricate testing than conventional small molecules, including biodistribution studies, immunogenicity assessment, vector safety evaluations, dose optimization, and long-term toxicology studies. Many small to mid-sized biotech firms in the U.S. lack the comprehensive in-house infrastructure for such studies, making outsourcing to CROs a viable and economical solution.

Technology adoption is one of the significant contributors to growth as U.S. preclinical CROs are increasingly employing advanced techniques, such as 3D cell culture models, organoids, patient-derived xenograft models, AI-driven data analytics, imaging platforms, high-throughput screening, and translational disease models. These innovations enhance the clinical relevance of preclinical data and enable sponsors to make more informed decisions before human trials. For instance, the use of 3D tumor models and sophisticated oncology platforms is enhancing the early assessment of cancer therapies. The market is further fueled by the rising prevalence of chronic diseases, including cancer, Alzheimer's disease, metabolic disorders, and cardiovascular conditions. As drug developers funnel more resources into therapies for these illnesses, the demand for preclinical testing continues to drive the market growth.

Furthermore, stringent U.S. FDA regulations necessitating safety, toxicity, and efficacy data prior to IND submission compel sponsors to collaborate with experienced CROs familiar with regulatory requirements. Thus, the U.S. preclinical CRO market is expected to witness new growth opportunities driven by robust drug development activities, rising outsourcing trends, an expanding array of advanced therapy pipelines, and an increasing need for specialized preclinical models.

U.S. Preclinical CRO Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. preclinical CRO market report based on service, development stage, indication, model type, and end use:

• Service Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Bioanalysis and DMPK studies
  • In vitro ADME
  • In-vivo PK
• Toxicology Testing
  • GLP
  • Non-GLP
• Compound Management
  • Process R&D
  • Custom Synthesis
  • Others
• Chemistry
  • Medicinal Chemistry
  • Computation Chemistry
• Safety Pharmacology
• Others
• Development Stage Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Target Discovery
• Preclinical Optimization, Efficacy & PK/PD
• IND-Enabling Safety (GLP)
• Bioanalysis & Analytics
• Indication Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Oncology
• CNS
• Infectious Diseases
• Cardiovascular Diseases
• Metabolic Disorders
• Rare Diseases
• Others
• Model Type Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• In Vitro
• In Vivo
• Ex Vivo
• End Use Outlook (Revenue, USD Million/Billion, 2021 - 2033)
• Pharmaceutical and Biopharmaceutical Companies
• Medical Device Companies
• Academic and Research Institutes
• Others

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
  • 1.2.2. Development Stage
  • 1.2.3. Indication
  • 1.2.4. Model Type
  • 1.2.5. End Use
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. U.S. Preclinical CRO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Value Chain Analysis
  • 3.6.1. Supply Trends
  • 3.6.2. Demand Trends
• 3.7. Market Analysis Tools
  • 3.7.1. Porter's Five Force Analysis
  • 3.7.2. PESTEL by SWOT Analysis

Chapter 4. U.S. Preclinical CRO Market: Service Estimates & Trend Analysis

• 4.1. U.S. Preclinical CRO Market, By Service: Segment Dashboard
• 4.2. U.S. Preclinical CRO Market, By Service: Movement Analysis
• 4.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million/Billion)
• 4.4. Bioanalysis and DMPK studies
  • 4.4.1. Bioanalysis and DMPK studies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.4.2. In vitro ADME
    • 4.4.2.1. In vitro ADME Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.4.3. In vivo PK
    • 4.4.3.1. In vivo PK Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.5. Toxicology Testing
  • 4.5.1. Toxicology Testing Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.5.2. GLP
    • 4.5.2.1. GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.5.3. Non-GLP
    • 4.5.3.1. Non-GLP Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.6. Compound Management
  • 4.6.1. Compound Management Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.6.2. Process R&D
    • 4.6.2.1. Process R&D Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.6.3. Custom Synthesis
    • 4.6.3.1. Custom Synthesis Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.6.4. Others
    • 4.6.4.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.7. Chemistry
  • 4.7.1. Chemistry Market Estimates & Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.7.2. Medicinal Chemistry
    • 4.7.2.1. Medicinal Chemistry Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.7.3. Computational Chemistry
    • 4.7.3.1. Computational Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.8. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
  • 4.8.1. Safety Pharmacology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 4.9. Others
  • 4.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 5. U.S. Preclinical CRO Market: Development Stage Estimates & Trend Analysis

• 5.1. U.S. Preclinical CRO Market, By Development Stage: Segment Dashboard
• 5.2. U.S. Preclinical CRO Market, By Development Stage: Movement Analysis
• 5.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Development Stage, 2021 - 2033 (USD Million/Billion)
• 5.4. Target Discovery
  • 5.4.1. Target Discovery Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.5. Preclinical Optimization, Efficacy & PK/PD
  • 5.5.1. Preclinical Optimization, Efficacy & PK/PD Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.6. IND-Enabling Safety (GLP)
  • 5.6.1. IND-Enabling Safety (GLP) Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 5.7. Bioanalysis & Analytics
  • 5.7.1. Bioanalysis & Analytics Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 6. U.S. Preclinical CRO Market: Indication Estimates & Trend Analysis

• 6.1. U.S. Preclinical CRO Market, By Indication: Segment Dashboard
• 6.2. U.S. Preclinical CRO Market, By Indication: Movement Analysis
• 6.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Indication, 2021 - 2033 (USD Million/Billion)
• 6.4. Oncology
  • 6.4.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.5. CNS
  • 6.5.1. CNS Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.6. Infectious Diseases
  • 6.6.1. Infectious Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.7. Cardiovascular Diseases
  • 6.7.1. Cardiovascular Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.8. Metabolic Disorders
  • 6.8.1. Metabolic Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.9. Rare Diseases
  • 6.9.1. Rare Diseases Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 6.10. Others
  • 6.10.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 7. U.S. Preclinical CRO Market: Model Type Estimates & Trend Analysis

• 7.1. U.S. Preclinical CRO Market, By Model Type: Segment Dashboard
• 7.2. U.S. Preclinical CRO Market, By Model Type: Movement Analysis
• 7.3. U.S. Preclinical CRO Market Estimates & Forecasts, By Model Type, 2021 - 2033 (USD Million/Billion)
• 7.4. In Vitro
  • 7.4.1. In vitro Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.5. In Vivo
  • 7.5.1. In Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 7.6. Ex Vivo
  • 7.6.1. Ex Vivo Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 8. U.S. Preclinical CRO Market: End Use Estimates & Trend Analysis

• 8.1. U.S. Preclinical CRO Market, By End Use: Segment Dashboard
• 8.2. U.S. Preclinical CRO Market, By End Use: Movement Analysis
• 8.3. U.S. Preclinical CRO Market Estimates & Forecasts, By End Use, 2021 - 2033 (USD Million/Billion)
• 8.4. Pharmaceutical and Biopharmaceutical Companies
  • 8.4.1. Pharmaceutical Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.5. Medical Device Companies
  • 8.5.1. Medical Device Companies Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.6. Academic and Research Institutions
  • 8.6.1. Academic and Research Institutions Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)
• 8.7. Others
  • 8.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million/Billion)

Chapter 9. Competitive Landscape

• 9.1. Key Participant Categorization
  • 9.1.1. Market Leaders
  • 9.1.2. Emerging Players
• 9.2. Market Assessment Analysis, 2025 (Heat Map Analysis)
• 9.3. Company Profiles
  • 9.3.1. Eurofins Scientific
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. ICON plc
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Medpace Holdings, Inc.
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Charles River Laboratories
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. PPD (Thermo Fisher Scientific, Inc.)
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. SGS SA (SGS Societe Generale de Surveillance SA.)
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Intertek Group plc (IGP)
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Labcorp
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Crown Bioscience
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives